ALK and neoplasm: In vivo and in vitro studies demonstrated that treatment with Hsp90 inhibitors such as 17-DMAG, ganetespib (STA-9090), or IPI-504 reduced protein levels of the ALK fusion protein, enhanced cell death, led to tumor regression, and prolonged survival of xenograft models [14, 15, 12].